DAMORA THERAPEUTICS, INC. Diluted Shares Outstanding (Weighted Average)
DAMORA THERAPEUTICS, INC. (DMRA) reported Diluted Shares Outstanding (Weighted Average) of 61.12 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 61.12M shares, a 4521.14% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 34.30M shares, a 2494.47% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 1.48M shares, a 12.66% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 1.33M shares, a 15.90% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 1.36M shares, a 17.79% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 1.16M shares, a 8.87% increase from fiscal 2023.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 1.06M shares, a 95.82% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 25.41M shares, a 0.58% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 61.12M shares 10-Q · filed 2026-08-10 | 47.45M shares 10-Q · filed 2026-08-10 | 32.30M shares derived: average of 3 quarters · filed 2026-08-10 | 24.56M shares derived: average of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | 34.30M shares 10-Q · filed 2026-05-12 | 17.89M shares derived: average of 2 quarters · filed 2026-05-12 | 12.37M shares derived: average of 3 quarters · filed 2026-05-12 | 9.61M shares derived: average of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | 1.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 1.40M shares derived: average of 2 quarters · filed 2026-03-19 | 1.38M shares derived: average of 3 quarters · filed 2026-08-10 | 1.36M shares 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | 1.33M shares 10-Q · filed 2025-11-06 | 1.32M shares derived: average of 2 quarters · filed 2026-08-10 | 1.32M shares 10-Q · filed 2025-11-06 | 1.32M shares derived: average of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | 1.32M shares 10-Q · filed 2026-08-10 | 1.32M shares 10-Q · filed 2026-08-10 | 1.32M shares derived: average of 3 quarters · filed 2026-08-10 | 1.28M shares derived: average of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | 1.32M shares 10-Q · filed 2026-05-12 | 1.32M shares derived: average of 2 quarters · filed 2026-05-12 | 1.26M shares derived: average of 3 quarters · filed 2026-05-12 | 1.22M shares derived: average of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | 1.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 1.23M shares derived: average of 2 quarters · filed 2026-03-19 | 1.18M shares derived: average of 3 quarters · filed 2026-03-19 | 1.16M shares 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | 1.14M shares 10-Q · filed 2025-11-06 | 1.11M shares derived: average of 2 quarters · filed 2025-11-06 | 1.10M shares 10-Q · filed 2025-11-06 | 1.10M shares derived: average of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | 1.08M shares 10-Q · filed 2025-08-05 | 27.12M shares 10-Q · filed 2024-08-12 | 1.08M shares 10-Q · filed 2025-08-05 | 27.11M shares 10-Q · filed 2024-08-12 | 1.08M shares derived: average of 3 quarters · filed 2025-08-05 | 1.08M shares derived: average of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | 1.08M shares 10-Q · filed 2025-05-08 | 27.11M shares 10-Q · filed 2024-04-29 | 1.08M shares derived: average of 2 quarters · filed 2025-05-08 | 1.08M shares derived: average of 3 quarters · filed 2025-05-08 | 7.41M shares derived: average of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | 1.08M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 1.08M shares derived: average of 2 quarters · filed 2025-03-19 | 9.51M shares derived: average of 3 quarters · filed 2025-03-19 | 1.06M shares 10-K · filed 2025-03-19 | 26.57M shares 10-K · filed 2024-03-08 | |||
| 2023-09-30 | 1.08M shares 10-Q · filed 2024-11-01 | 27.10M shares 10-Q · filed 2023-11-06 | 13.73M shares derived: average of 2 quarters · filed 2024-11-01 | 1.06M shares 10-Q · filed 2024-11-01 | 26.39M shares 10-Q · filed 2023-11-06 | 19.69M shares derived: average of 4 quarters · filed 2024-11-01 | ||
| 2023-06-30 | 26.38M shares 10-Q · filed 2024-08-12 | 26.03M shares 10-Q · filed 2024-08-12 | 25.89M shares derived: average of 3 quarters · filed 2024-08-12 | 25.79M shares derived: average of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | 25.67M shares 10-Q · filed 2024-04-29 | 25.64M shares derived: average of 2 quarters · filed 2024-04-29 | 25.59M shares derived: average of 3 quarters · filed 2024-04-29 | 25.51M shares derived: average of 4 quarters · filed 2024-04-29 | ||||
| 2022-12-31 | 25.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 25.55M shares derived: average of 2 quarters · filed 2024-03-08 | 25.46M shares derived: average of 3 quarters · filed 2024-03-08 | 25.41M shares 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | 25.49M shares 10-Q · filed 2023-11-06 | 25.38M shares derived: average of 2 quarters · filed 2023-11-06 | 25.34M shares 10-Q · filed 2023-11-06 | 25.32M shares derived: average of 4 quarters · filed 2023-11-06 | ||||
| 2022-06-30 | 25.27M shares 10-Q · filed 2023-07-31 | 25.27M shares 10-Q · filed 2023-07-31 | 25.26M shares derived: average of 3 quarters · filed 2023-07-31 | 25.26M shares derived: average of 4 quarters · filed 2023-07-31 | ||||
| 2022-03-31 | 25.26M shares 10-Q · filed 2023-04-28 | 25.26M shares derived: average of 2 quarters · filed 2023-04-28 | 25.26M shares derived: average of 3 quarters · filed 2023-04-28 | |||||
| 2021-12-31 | 25.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 25.26M shares derived: average of 2 quarters · filed 2023-03-09 | 25.26M shares 10-K · filed 2023-03-09 | |||||
| 2021-09-30 | 25.26M shares 10-Q · filed 2022-11-08 | 25.26M shares 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |